Global AI in Respiratory Diseases Market Size Study & Forecast, By Imaging Type (Magnetic Resonance Imaging (MRI), Computed Tomography (CT) Scan, Electronic Patient-Reported Outcomes (ePRO)) By Indication (Chronic Obstructive Pulmonary Disease, Interstiti

Global AI in Respiratory Diseases Market Size Study & Forecast, By Imaging Type (Magnetic Resonance Imaging (MRI), Computed Tomography (CT) Scan, Electronic Patient-Reported Outcomes (ePRO)) By Indication (Chronic Obstructive Pulmonary Disease, Interstitial Lung Disease, Pulmonary Infection) By End Use (Hospital, Diagnostic Centers, Ambulatory Surgical Centers, Other End-Users) and Regional Analysis, 2023-2030

Global AI in Respiratory Diseases Market is valued at approximately USD xx billion in 2022 and is anticipated to grow with a healthy growth rate of more than xx% over the forecast period 2023-2030. AI in Respiratory Diseases refers to the application of artificial intelligence (AI) techniques and technologies in the diagnosis, management, treatment, and research of respiratory conditions including asthma, chronic obstructive pulmonary disease (COPD), pneumonia, lung cancer, and others. The AI in Respiratory Diseases market is expanding because of factors such as the rising prevalence of asthma and growing cases of chronic obstructive pulmonary disease. AI algorithms can analyze medical images such as chest X-rays, CT scans, and MRI scans to detect abnormalities indicative of respiratory diseases. As a result, the demand for AI in Respiratory Diseases has progressively increased in the international market during the forecast period 2023-2030.

AI-powered devices and software can allow for remote monitoring of asthma symptoms and medication adherence. Considering the growing frequency of asthma, there is a demand for remote monitoring technologies that can assist patients in efficiently managing their illness outside of clinical settings. Artificial intelligence can analyze data from wearable devices and patient-reported outcomes to provide information on illness progression and therapy efficacy. According to the Asthma and Allergy Foundation of America, every day, an average of 10 lives are lost to asthma in the United States. In the year 2021, the toll of asthma claimed 3,517 lives in the country. Furthermore, AI can leverage predictive analytics to forecast asthma exacerbations and identify high-risk patients who may require proactive intervention. Another important factor that drives the AI in Respiratory Diseases market is increasing cases of chronic obstructive pulmonary disease. AI algorithms can analyze individual patient data to tailor treatment plans based on factors such as disease severity, comorbidities, and response to therapy. This personalized approach can optimize treatment efficacy and minimize adverse effects. In addition, as per the World Health Organization, respiratory disease infection is considered the third major cause of death with approximately 3 million deaths per year, out of which nearly 90% of COPD fatalities occur in those 70-year-old people from low-and middle-income countries. Also, there are around 262 million patients estimated to suffer from asthma, which commonly affects children. Moreover, technological advancements related to AI integrated respiratory devices and the growing demand for personalized treatment for respiratory disease are anticipated to create a lucrative growth opportunity for the market over the forecast period. However, the high cost of AI based technology and lack of operational expertise is going to impede overall market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global AI in Respiratory Diseases Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the increasing funding for research and development in AI technology in the region. Increased funding can promote collaboration among AI researchers, physicians, pharmaceutical companies, and healthcare organizations, allowing for the exchange of data, skills, and resources to enhance AI-driven advances in respiratory disease management. According to ExecutiveGov, in 2022, the United States government has invested USD 4.8 billion in AI research and development to support programs that advance AI based smart health technologies and data science. The region’s dominant performance is anticipated to propel the overall demand for AI in Respiratory Diseases. Furthermore, Asia Pacific is expected to grow fastest during the forecast period, owing to factors such as the rising geriatric population in the region. Geriatric patients often have multiple comorbidities and may present with atypical symptoms, making early detection and accurate diagnosis crucial for effective management of respiratory diseases. AI-powered tools can assist healthcare providers in identifying patterns and markers indicative of respiratory conditions, facilitating early intervention and personalized treatment plans.

Major market players included in this report are:
Siemens Healthineers AG
GE HealthCare Technologies, Inc.
Verily Life Sciences LLC
Philips Healthcare
Dectrocel Healthcare And Research Pvt Ltd.
Icometrix NV
Infervision UK LTD.
PneumoWave Inc.
Respiray LLC
Thirona B.V.

Recent Developments in the Market:
 In April 2024, Clario, a healthcare research and technology business that provides the top endpoint technology solutions for clinical trials, acquired the technology startup ArtiQ. This acquisition increases the capability of artificial intelligence (AI) in Clario's Respiratory Solutions portfolio and strengthens the company's capacity to harness and build breakthrough AI applications across its service lines.

Global AI in Respiratory Diseases Market Report Scope:
 Historical Data – 2020 - 2021
 Base Year for Estimation – 2022
 Forecast period - 2023-2030
 Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
 Segments Covered - Imaging Type, Indication, End Use, Region
 Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define the market sizes of different segments & countries in recent years and to forecast the values for the coming years. The report is designed to incorporate qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters to detailed information about the crucial aspects such as driving factors & challenges that will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with a detailed analysis of the competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Imaging Type
Magnetic Resonance Imaging (MRI)
Computed Tomography (CT) Scan
Electronic Patient-Reported Outcomes (ePRO)

By Indication
Chronic Obstructive Pulmonary Disease
Interstitial Lung Disease
Pulmonary Infection

By End Use
Hospital
Diagnostic Centers
Ambulatory Surgical Centers
Other End-Users

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico
RoLA

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.